儿童小阴茎治疗软膏
Search documents
快讯:长春高新新药获批引爆股价
Xin Lang Cai Jing· 2026-02-26 02:27
0.000 .. -4.701 ■ 在 rota to 新浪财经客户端 2 2 1 3 A sina the Sina Finance Mobile Version er 論 193 limily.all(... billathal) 来源:股市直击 2月26日,生物制品板块短线拉升,长春高新触及涨停,三生国健涨超7%,欧林生物、特宝生物、荣昌 生物跟涨。 长春高新受到关注的核心驱动力来自创新药领域的多项关键突破。公司自研的全球首款儿童小阴茎治疗 软膏获批临床,伏欣奇拜单抗作为国内首个IL-1β单抗上市后销售强劲且多地缺货。更重要的是, GenSci098注射液获得13.65亿美元海外BD大单且首付款已到账,为公司带来重大业务增量。公司正从 传统生长激素业务向肿瘤、免疫、内分泌等多管线创新药转型,这些积极进展引发市场广泛关注。 ...
今日十大热股:包钢股份领衔稀土板块爆发,长春高新全球首款儿童小阴茎治疗软膏获批临床
Jin Rong Jie· 2026-02-26 01:27
Market Overview - On February 25, the Shanghai Composite Index rose by 0.72% to 4147.23 points, the Shenzhen Component Index increased by 1.29% to 14475.86 points, and the ChiNext Index climbed by 1.41% to 3354.82 points. The total trading volume in the Shanghai and Shenzhen markets reached 2.46 trillion yuan, an increase of approximately 260.48 billion yuan compared to the previous trading day. A total of 3540 stocks rose, 1529 fell, and 121 remained unchanged, with thematic sectors showing strong performance [1]. Popular Stocks - The top ten popular stocks in A-shares include Baogang Group, Aerospace Development, Changchun High-tech, Yuntianhua, Hancable, Northern Rare Earth, Hebang Biotechnology, Jinzhengdai, Chuanjinnuo, and Lioo [1][2]. Baogang Group - Baogang Group's market attention is driven by its advantages in rare earth resources and the effectiveness of its strategic transformation. The price of rare earth concentrate has been raised for the sixth consecutive time, indicating an improvement in its bargaining power within the rare earth industry chain. The production of rare earth steel reached a historical high of 1.5 million tons, supported by its exclusive supply rights from the world's largest rare earth mine [3]. Aerospace Development - Aerospace Development's rise in popularity is attributed to dual advancements in governance optimization and strategic layout. The company has recently completed a standardized board of directors' restructuring and revised several management systems. Its subsidiary, Aerospace Tianmu, is advancing the "Tianmu No. 1" satellite project through capital increase and expansion, enhancing its strategic positioning in military informationization and commercial aerospace [3]. Changchun High-tech - Changchun High-tech is gaining attention due to significant breakthroughs in the innovative drug sector. The company has received clinical approval for the world's first ointment for treating pediatric micropenis and has strong sales for its IL-1β monoclonal antibody. Additionally, it secured a $1.365 billion overseas business development contract, marking a substantial business increment [4]. Yuntianhua - Yuntianhua's market interest stems from its resource advantages and external demand. The company possesses nearly 800 million tons of phosphate reserves with a self-sufficiency rate of 100%. The production of its 100,000-ton iron phosphate project has commenced, and the upcoming spring farming season is expected to boost phosphate fertilizer demand [4]. Hancable - Hancable's popularity is driven by technological advantages underpinned by policy support. The State Grid's investment plan of 4 trillion yuan is expected to stimulate demand for high-end cables, particularly in ultra-high voltage and flexible direct current sectors. The company has core technologies in ±535kV submarine cables and has optimized its governance structure to enhance competitiveness [5]. Northern Rare Earth - Northern Rare Earth's market focus is influenced by policy, supply-demand dynamics, and performance. As a leader in the rare earth industry, the company benefits from national protection policies and the tightening of supply controls, which have improved the supply-demand balance and driven up rare earth prices. The company's net profit is expected to increase by 116.67% to 1.346 billion yuan [5]. Hebang Biotechnology - Hebang Biotechnology's rise is linked to resource layout and positive business developments. The company has obtained exploration rights for over 1,000 square kilometers of gold mines in Australia and is advancing multi-metal mining projects in Xinjiang. Its methionine business is experiencing growth, and external factors such as rising commodity prices are enhancing profitability [6]. Jinzhengdai, Chuanjinnuo, and Lioo - Jinzhengdai is benefiting from increased attention in the fertilizer industry, with rising domestic urea prices and improved governance structure. Chuanjinnuo is seeing a significant profit increase of 144%-180% due to international phosphate prices exceeding $700 per ton. Lioo has capitalized on AI marketing and liquid cooling server trends, achieving a net profit increase of 469.1% [6].